Assetmark Inc. Buys 34,057 Shares of Bristol Myers Squibb Company $BMY

Assetmark Inc. grew its position in Bristol Myers Squibb Company (NYSE:BMY) by 16.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 240,622 shares of the biopharmaceutical company’s stock after purchasing an additional 34,057 shares during the period. Assetmark Inc.’s holdings in Bristol Myers Squibb were worth $10,852,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC lifted its holdings in Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 4,935 shares during the period. Sivia Capital Partners LLC raised its stake in shares of Bristol Myers Squibb by 59.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock worth $346,000 after purchasing an additional 2,786 shares during the period. Foster & Motley Inc. boosted its holdings in shares of Bristol Myers Squibb by 34.7% in the 2nd quarter. Foster & Motley Inc. now owns 51,493 shares of the biopharmaceutical company’s stock worth $2,384,000 after buying an additional 13,268 shares during the last quarter. Koshinski Asset Management Inc. increased its holdings in Bristol Myers Squibb by 6.7% during the second quarter. Koshinski Asset Management Inc. now owns 27,695 shares of the biopharmaceutical company’s stock worth $1,282,000 after buying an additional 1,739 shares during the last quarter. Finally, United Bank raised its position in Bristol Myers Squibb by 15.0% in the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after acquiring an additional 3,277 shares during the period. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Stock Up 1.3%

Shares of NYSE BMY opened at $60.64 on Monday. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The company has a market cap of $123.49 billion, a P/E ratio of 17.58, a P/E/G ratio of 0.17 and a beta of 0.29. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33. The business has a 50-day simple moving average of $55.33 and a two-hundred day simple moving average of $49.48.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. During the same quarter in the prior year, the company earned $1.67 earnings per share. The company’s quarterly revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date was Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Analyst Ratings Changes

BMY has been the subject of a number of research reports. Citigroup increased their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Cantor Fitzgerald reissued a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, November 24th. Scotiabank restated a “sector perform” rating and issued a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. Guggenheim reiterated a “buy” rating and set a $72.00 price target (up previously from $62.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Finally, Morgan Stanley reiterated an “underweight” rating and set a $40.00 target price on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Eight investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $59.20.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.